siRNA for Influenza Therapy.
siRNA for Influenza Therapy.
复制标题
DOI：
10.3390/v2071448
复制
发表时间：
2010-07
期刊：
影响因子：
--
通讯作者：
Barik S
中科院分区：
文献类型：
--
作者：
Barik S
流感病毒是人类最普遍和最古老的感染之一。每年约有五分之一的世界人口感染流感病毒，导致高发病率和死亡率，特别是在婴儿、老年人和免疫功能低下者中。仅在美国，流感爆发每年就导致大约30，000人死亡。目前的疫苗和抗流感药物由于病毒的高突变率和副作用而使用有限。近年来，由合成的短干扰RNA（siRNA）触发的RNA干扰已迅速发展为有效的抗病毒方案。已显示适当设计的siRNA作为流感病毒复制的有效抑制剂起作用。siRNA在许多领域优于传统的小分子抗病毒药物，例如易于设计，成本适中和快速周转。虽然特异性和组织递送仍然是RNAi临床应用的主要瓶颈，但针对呼吸道病毒（包括但不限于流感病毒）的siRNA的鼻内应用已经取得了显著的成功和乐观，本文对此进行了综述。
Influenza virus is one of the most prevalent and ancient infections in humans. About a fifth of world’s population is infected by influenza virus annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised. In the US alone, influenza outbreaks lead to roughly 30,000 deaths each year. Current vaccines and anti-influenza drugs are of limited use due to high mutation rate of the virus and side effects. In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA), has rapidly evolved as a potent antiviral regimen. Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication. The siRNAs outperform traditional small molecule antivirals in a number of areas, such as ease of design, modest cost, and fast turnaround. Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism, which is reviewed here.
登录
查看更多内容
影响因子：
46.9
作者：
Judge, AD;Sood, V;MacLachlan, I
通讯作者：
MacLachlan, I
影响因子：
11.4
作者：
Aszódi, A;Pfeifer, A;Fässler, R
通讯作者：
Fässler, R
影响因子：
5.4
作者：
Elton, D;Simpson-Holley, M;Digard, P
通讯作者：
Digard, P
DOI：
10.1073/pnas.0812085106
发表时间：
2009-05-19
影响因子：
11.1
作者：
Gu, Wenyi;Cochrane, Melanie;McMillan, Nigel A. J.
通讯作者：
McMillan, Nigel A. J.
影响因子：
5
作者：
Ge, Q;Eisen, HN;Chen, JZ
通讯作者：
Chen, JZ